Clinical Trials Browser

Recruiting × INDUSTRY × Prostatic Diseases × Clear all

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05413850 2026-03-02

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Phase 1/2 Recruiting

82 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06785636 2025-11-14

P300

Phase 1/2 Recruiting

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT04597411 2025-03-21

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Phase 1 Recruiting

99 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06190899 2025-03-21

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Clinical Trials

STRIKE-001

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

P300

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer